Trial Profile

A Phase 2a, Randomized, Placebo-controlled, Double-blind Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AGMB-129 in Patients With Fibrostenotic Crohn's Disease

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 09 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 May 2025 According to Agomab Therapeutics NV media release, the company is on track to report results on 103 patients in the fourth quarter of this year.
06 May 2025 According to Agomab Therapeutics NV media release, The interim results from this study were presented by Florian Rieder, MD, at Digestive Disease Week 2025, taking place in San Diego on May 3-6, 2025.
06 May 2025 Interim Results (n=44)presented at the Agomab Therapeutics NV Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com